X4 Pharmaceuticals, Inc XFOR
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
3/9
Piotroski F — financial health
-1.48
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $6.5M | -$79.2M | — | — | $186.3M |
| 2024 | $2.6M | -$37.5M | — | -$131.2M | $22.1M |
| 2023 | $0 | -$101.2M | — | -$96.6M | $51.1M |
| 2022 | $0 | -$93.9M | — | -$77.2M | $74.1M |
| 2021 | $0 | -$88.7M | — | — | $64.4M |
| 2020 | $3.0M | -$62.1M | — | — | $72.8M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| KIRSKE DAVID | Chief Financial Officer | 2026-05-12 | Sell | 16,961 | $4.29 |
| Craig Adam R | Executive Chairman | 2025-10-23 | Buy | 86,206 | $2.90 |
| Volpone John | President | 2025-08-14 | Grant | 289,881 | — |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -1.48 (distress)
- Working capital / assets 0.812
- Retained earnings / assets -2.047
- EBIT / assets -0.299
- Equity / liabilities 1.788
Source: SEC EDGAR filings · CIK 0001501697 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.